Skip to content
Screener

Revolution Medicines, Inc. RVMD Q4 2025 Annual earnings

Reported February 25, 2026 · After market close

Revenue-
EPS-$1.86Miss by $0.28
EPS estimate-$1.58

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$13.4M
EPS estimate-$2.44

Financials

Q4 2025

Income statement

See full
Revenue-—
Operating income-$361.6M-67.2%
Net income-$364.9M-87.5%
EPS (diluted)-$1.89-67.3%

Balance sheet

See full
Cash & equivalents$383.7M-29.3%
Total debt$158.7M+16.8%
Total equity$1.6B-28.0%
Total assets$2.4B-8.0%

Cash flow

See full
Operating cash flow-$274.2M-98.3%
CapEx$1.9M+57.5%
Free cash flow-$276.2M-97.9%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$15.4B+90.5%
Enterprise value$15.17B+97.7%

Returns & leverage

See full
Return on equity-58.1%+2,775pp
Debt / equity0.1×0.0×
Current ratio7.1×-7.1×

FAQ

When did Revolution Medicines, Inc. report Q4 2025 earnings?
Revolution Medicines, Inc. (RVMD) reported Q4 2025 earnings on February 25, 2026 after market close.
What were Revolution Medicines, Inc.'s Q4 2025 revenue and EPS?
Revolution Medicines, Inc. reported revenue of - and eps of $-1.86 for Q4 2025.
Did Revolution Medicines, Inc. beat estimates in Q4 2025?
EPS missed the consensus estimate of $-1.58 by $0.28.
How did Revolution Medicines, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $261.6M a year earlier and eps declined 66.1% from $-1.12.
Where can I find Revolution Medicines, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-071517) and the 10-K periodic report (0001193125-26-071563) directly on SEC EDGAR. The filing index links above go to sec.gov.